Eagle Health Investments LP Takes $18.39 Million Position in Boston Scientific Corporation $BSX

Eagle Health Investments LP acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 293,152 shares of the medical equipment provider’s stock, valued at approximately $18,395,000. Boston Scientific makes up approximately 3.2% of Eagle Health Investments LP’s holdings, making the stock its 14th biggest position.

Other large investors have also recently made changes to their positions in the company. Outfitters Financial LLC raised its holdings in Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock valued at $2,291,000 after acquiring an additional 110 shares in the last quarter. Natural Investments LLC grew its holdings in Boston Scientific by 2.9% during the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock worth $384,000 after acquiring an additional 112 shares in the last quarter. Patton Fund Management Inc. increased its position in shares of Boston Scientific by 5.5% in the 4th quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider’s stock valued at $217,000 after purchasing an additional 118 shares during the last quarter. Bridgewater Advisors Inc. increased its position in shares of Boston Scientific by 1.2% in the 4th quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider’s stock valued at $921,000 after purchasing an additional 123 shares during the last quarter. Finally, Earned Wealth Advisors LLC raised its holdings in shares of Boston Scientific by 5.2% in the 4th quarter. Earned Wealth Advisors LLC now owns 2,647 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 131 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders bought 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Up 3.0%

Shares of NYSE BSX opened at $45.56 on Tuesday. The stock has a market cap of $67.72 billion, a PE ratio of 19.06, a price-to-earnings-growth ratio of 0.85 and a beta of 0.58. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The business has a 50-day moving average price of $47.00 and a 200 day moving average price of $63.47.

Boston Scientific declared that its Board of Directors has initiated a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BSX. Jefferies Financial Group decreased their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Stifel Nicolaus dropped their target price on Boston Scientific from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, June 25th. Bank of America cut their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Evercore set a $65.00 price target on Boston Scientific in a report on Monday, July 6th. Finally, Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $79.64.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.